Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APH-1902
- Development stage
- Preclinical
- Lead developer
- Aphios
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Perfusion
01
Overview
APH-1902 is a therapeutic candidate developed by Aphios Corporation for the mitigation of ischemia-reperfusion injury (IRI) during organ transplantation, with a primary focus on kidney transplantation. It consists of a hydrogen sulfide (H2S) donor encapsulated within a nanoparticle delivery system using Aphios' proprietary Critical Fluid Technology. Hydrogen sulfide is a gasotransmitter that provides potent antioxidant, anti-inflammatory, and cytoprotective effects. By delivering H2S in a controlled manner directly to the transplant graft or systemically to the recipient, APH-1902 aims to improve organ viability, enhance transplantation success rates, and increase the availability of donor organs. The project has received support from the National Institutes of Health (NIH) for preclinical development, including evaluation in porcine models of donation after circulatory death (DCD) kidney transplantation.
- Other names
- Nanoencapsulated hydrogen sulfide donor
02
Targets
NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)KATP channel (ATP-sensitive potassium channel)
Beyond the preview
Go deeper on APH-1902.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APH-1902.